Showing posts with label Equity Research. Show all posts
Showing posts with label Equity Research. Show all posts

June 20, 2012

Quick Hits for June 20

I don't expect to blog much, if at all, until the beginning of next week. In the interim, some quick hits...


For readers who know me, you also know I'm currently on a family summer road trip, which I also refer to as our 4th annual Griswoldesque vacation. The road trip is a uniquely American rite of passage.


 

Dr. Agarwala's Munich presentation is at the end of this week, on Friday, June 22 (morning, Munich time). The MM P2 data being finalized, which this presentation marks, is important. Like Maxim noted on June 8, I [obviously] expect positive results. Much more importantly, I also expect such positive results to be very interesting.

My current expectation is the company could (should) report receipt of the SPA for the MM pivotal Phase 3 trial by the end of June, which is next week. It is possible we do not hear until the middle of July (I hope not much later than this). Management's current guidance is best case Q2 and base case Q3.

While Provectus' pursuit of the SPA for MM is designed around a clinical and business strategy to pursue approval for the intralesional delivery of PV-10 for local-regional treatment of Stage 3 and early Stage 4 MM, Moffitt's work is directly aimed at validating and further demonstrating the systemic benefit of the drug and therefore its use as such. This underscores the nature of the pursuit of accelerated approval for PV-10, a parallel path to management's work with the FDA to achieve the SPA. As a result, more information on Moffitt's work is very highly anticipated. Does Moffitt know their place in history?

While one cannot project timing of the regulatory path, one could argue PV-10 approval, now, is a certainty.

Craig is presenting at InvestTennessee on Thursday, June 21 at 10:45 am ET. Eric and Peter are in Munich.

The path to and timing of a dermatology deal likely will hinge on a review of the final psoriasis Phase 2 data by prospective partners as well as their take on the FDA's view of PV-10 toxicity or, more to the point, lack thereof. While it does not appear we're quite there yet, it does appear it might be soon.

The annual meeting is next Thursday, June 28 at 4 pm ET. If you have not yet voted your shares, you should. Voting allows you to voice your opinion of management and their approach, whether you agree  or disagree with them, and agree or disagree with some or all of their business tactics and strategy.

Current cash balances, combined with likely monthly cash burn estimates, suggest a comfortable situation (operating runaway) for the near- to medium-term until one or more triggers or catalysts play out. Big pharma understands management has the ability to raise the money it needs (of course, money comes at a price).

June 12, 2012

Why Use A Local Agent To Treat A Systemic Disease?

There is a two-fold reason for why the share price is where it is. The first reason relates to PV-10 being a local agent. The second relates to there being no "name" in the stock (I will address in a subsequent post).

Why use a local agent to treat a systemic disease? This, by far, probably is the biggest issue management must deal with in discussions with very serious life science constituents, including the FDA, Big Pharma, fundamental life science investors and equity research.

To be clear, Provectus is pursuing a focused label, one that enables intralesionally-deliver PV-10 to be local-regionally treat Stage 3 and early Stage 4 patients with metastatic melanoma. The receipt of the SPA, either this month (management's guidance: best case Q2; me: later this month) or next month (management: base case Q3; me: if not late-June, than early-July), describes the specifics of the regulatory path for PV-10 as a local agent. As a result, the share price should pop to reflect the addressable market opportunity of the local agent: use the local agent to treat the local disease.

Should Provectus stock rise to $2 or $3 per share (irrespective of what capital market dynamics occur because of a move from the OTC to the NASDAQ, a $200-300 million market capitalization would not seem unreasonable for a local agent-oriented biotechnology company. Vical, for example, has a market cap of about $265MM.

But, no local agent has ever been approved by the FDA for systemically treating cancer. And the addressable market opportunity to systemically treat MM and other cancer indications is the home run, and when the market cap could rise into the billions.

No one questions now that PV-10 works systemically, but life science constituents simply do not know why the drug works systemically. Until they understand, the default view will be to use the local agent to treat the local disease -- by definition. The release of more information from Moffitt, to elucidate why the drug works systemically, to further demonstrate its systemic efficacy, to further demonstrate is multi-indication viability, and to demonstrate its systemic benefit on humans, greatly informs those who want to understand why the drug works the way it does.

As a result, this kind of elucidation provides a forum for the FDA to analyze, assess and, we hope, approve a local agent for systemically treating cancer: accelerated approval.

This is why coupling the SPA milestone with the additional Moffitt work is important. The proximity to a dramatic rise in the share price, reflective of immense intrinsic value, has never been closer in the history of the company.

April 13, 2012

Provectus Pharmaceuticals Started At Buy By Roth Capital

Roth Capital Partners initiated equity research coverage of Provectus this week with a Buy rating and a $3.00 12-month price target. See here for:
Roth initiated coverage because of their biotech analyst Dr. Yale Jen, who previously covered Provectus for Maxim and was very knowledgeable of Provectus and PV-10/PH-10. See here (read Provectus has a new lead research analyst covering them at Maxim Group). Jen had a $3.50 12-month price target while he was at Maxim (his last note was January 18).

There are several items of varying interest in Jen's initiation note. One that stands out is this:
"Substantial unmet needs exist for advanced melanoma treatment despite the entrants of two recently-approved drugs. One of the major investor concerns is whether PV-10 would have an appropriate disease setting in the melanoma space to exhibit its value given two new drugs [Yervoy from Bristol-Myers Squibb (BMY – NC) and Zelboraf from Roche (RHHBY – NC)] recently (both in 2011) have been approved in the U.S. and Europe as treatment for late stage (Stage IIIb, IIIc and Stage IV) melanoma. We view this as an overblown concern. First, despite Yervoy demonstrating improved median OS (mOS) benefits from its pivotal clinical study, the shortcoming of the drug is amore serious side effect profile (with a Black Box warning) and high costs (~$120,000 annually). In addition, although Yervoy’s approved indication broadly covers late stage melanoma (Stage III and IV), approximately 90% of patients in the Yervoy pivotal trial were of Stage IV M1b and IV M1c; while Stage III patients accounted for only 1.5%. Together, we believe Yervoy could be used more appropriately for Stage IV melanoma patients if a more fitting therapy is available for Stage III patients and should be reserved for patients as potentially a last-resort option. Further, in current real world practice, Yervoy has been prescribed more for late stage, instead of Stage III, melanoma patients. Zelboraf (vemurafenib) is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF v600E mutation (account for ~46% of total cases) as detected by an FDA-approved test. Together, given the significant differences of the five-year survival rate exit between Stage IIIC and Stage VI melanoma (40% vs. 15%), in our opinion, it would be valuable to treat and prevent Stage III melanoma patients from advancing into Stage IV. As such, we believe PV-10, if clinically successful, could fulfill this unmet medical need, particularly with its lower cost and relatively easy administration. We estimate annual peak market potential for PV-10 in melanoma could reach $380MM based on a price assumption for PV-10 in the U.S. of $5,100 per vial with average annual treatment of approximately 6 vials, or annual costs of $35,000."
Rodman & Renshaw, Maxim Group and Stonegate Securities currently cover the company. R&R and Maxim have provided investment banking services to the company; primarily or exclusively fund raising or placement services (i.e., PIPEs). All of these investment banks, including Roth, are small boutique banks that cover small cap or smaller companies.

As a reminder, "small cap" is a company with a market capitalization of between $300 million and $2 billion. "Micro cap," a term which more aptly describes Provectus,  is a company with a market capitalization of between $50 million and $300 million. These definitions comes from Investopedia, although people may quibble with the boundaries.

Equity research on Wall Street has been broken for many, many years, pre- and post-2003's Global Research Settlement. And there is no meaningful solution in sight. This is not meant as a criticism of the analysts, but rather the investment banking firms for which they work. There are many good and great analysts who provide insightful and comprehensive coverage of publicly traded companies; however, their salaries and other related expenses still are supplemented or paid for by investment banking revenues. The not-so-dirty-little-secret on Wall Street is "pay-to-play" for non-large companies: Equity coverage in exchange for a deal (e.g., a fund raising or PIPE, an M&A transaction, etc.), or coverage in hopes of a deal.

Getting additional coverage like Roth and, previously, Stonegate, where there is no implicit or explicit promise by Provectus management of investment banking work is no small feat. By investment banking work I am referring to fees generated from fund raising and placements, M&A transactions and deal representation. Investment banking revenues derive from assisting companies involved in raising money and M&A, but also providing ancillary services (e.g., market making, trading of derivatives, fixed income instruments, foreign exchange, commodities, and equity securities). Roth makes a market in Provectus stock (as does R&R and Maxim).

Another broken aspect of equity coverage is that large cap companies enjoy dramatically more coverage than their smaller counterparts. Goldman Sachs Asset Management (GSAM) produced a white paper in 2011 entitled The Case for a Systematic Approach to Small Cap Investing. In it, they note that small cap firms have less research coverage than large cap firms:
"Large cap firms have over twice the amount of research coverage of small cap firms. As shown in the following chart, small cap firms fall under less analyst scrutiny than their large cap counterparts, as would be expected given their market cap representation as well as the larger number of small cap companies overall. Less coverage in the small cap universe can provide substantial opportunity for active managers to add value in small cap equity investing. We believe a quantitative approach has the ability to effectively track analyst ratings across the entire investment universe and can monitor any changes in analyst sentiment, even for those firms that are less researched, on a daily basis.  
We believe it is more likely that large cap securities, which are more closely followed relative to their small cap counterparts, may have prices that more accurately reflect their intrinsic value. This may provide more return opportunities for small cap equities and lends itself to a quantitative investment approach, where managers can assess the entire universe of securities based on a number of fundamental and behavioral factors."

Coverage by 4 small boutique banks is good. What will be more telling is when coverage comes from larger and top tier investment banks.

It is comforting and impressive to note, however, that the company's unnamed financial adviser is on the list of the link I just provided. Way up the list...